Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

CTP-543 is generally safe for treating alopecia areata.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

MK-5108 is safe and shows potential against tumors, especially alone.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

Tofacitinib treatment for hair loss may worsen acne.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.